CLINICAL TRIALS PROFILE FOR RUBOXISTAURIN
✉ Email this page to a colleague
Clinical Trials for Ruboxistaurin
Trial ID | Title | Status | Sponsor | Phase | Summary |
---|---|---|---|---|---|
NCT00044395 ↗ | Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes | Completed | Eli Lilly and Company | Phase 3 | The purpose of this protocol is to determine if an investigational drug is effective in treating nerve malfunction in diabetes. |
NCT00044408 ↗ | Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes | Completed | Chromaderm, Inc. | Phase 3 | The purpose of this protocol is to determine if an investigational drug known as LY333531 is effective in treating nerve malfunction in diabetes. |
NCT00044421 ↗ | Treatment of Peripheral Neuropathy in Patients With Diabetes | Completed | Eli Lilly and Company | Phase 3 | The purpose of this protocol is to determine if an investigational drug is effective in treating nerve malfunction in diabetes. |
NCT00090519 ↗ | Reduction in the Occurrence of Center-Involved Diabetic Macular Edema | Completed | Chromaderm, Inc. | Phase 3 | The purpose of this study is to determine if ruboxistaurin can help slow the worsening of an eye disease called macular edema in patients with diabetes. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Ruboxistaurin
Condition Name
Clinical Trial Locations for Ruboxistaurin
Trials by Country
Clinical Trial Progress for Ruboxistaurin
Clinical Trial Phase
Clinical Trial Sponsors for Ruboxistaurin
Sponsor Name